Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Growth 2022-2028
The global market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States DPP-4 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China DPP-4 Inhibitors for Type 2 Diabetes Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key DPP-4 Inhibitors for Type 2 Diabetes Treatment players cover Merck, AstraZeneca, Eli Lilly and Company, Novartis and Boehringer Ingelheim, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, with both quantitative and qualitative data, to help readers understand how the DPP-4 Inhibitors for Type 2 Diabetes Treatment market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in M Units.
Market Segmentation:
The study segments the DPP-4 Inhibitors for Type 2 Diabetes Treatment market and forecasts the market size by Type (Sitagliptin, Linagliptin and Vildagliptin), by Application (Offline Retail Pharmacy, Hospitals and Clinics and E-commerce and Internet Medical Care,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Sitagliptin
Linagliptin
Vildagliptin
Saxagliptin
Alogliptin
Others
Segmentation by application
Offline Retail Pharmacy
Hospitals and Clinics
E-commerce and Internet Medical Care
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Merck
AstraZeneca
Eli Lilly and Company
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Takeda Pharmaceutical
Mitsubishi Tanabe Pharma
LG Life Sciences
Sanwa Kagaku Kenkyusho
Dong-A Pharmaceuticals
Chapter Introduction
Chapter 1: Scope of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Research Methodology, etc.
Chapter 2: Executive Summary, global DPP-4 Inhibitors for Type 2 Diabetes Treatment market size (sales and revenue) and CAGR, DPP-4 Inhibitors for Type 2 Diabetes Treatment market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: DPP-4 Inhibitors for Type 2 Diabetes Treatment sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global DPP-4 Inhibitors for Type 2 Diabetes Treatment sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global DPP-4 Inhibitors for Type 2 Diabetes Treatment market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Merck, AstraZeneca, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma and LG Life Sciences, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for DPP-4 Inhibitors for Type 2 Diabetes Treatment by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for DPP-4 Inhibitors for Type 2 Diabetes Treatment by Country/Region, 2017, 2022 & 2028
2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type
2.2.1 Sitagliptin
2.2.2 Linagliptin
2.2.3 Vildagliptin
2.2.4 Saxagliptin
2.2.5 Alogliptin
2.2.6 Others
2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
2.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
2.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue and Market Share by Type (2017-2022)
2.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Type (2017-2022)
2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application
2.4.1 Offline Retail Pharmacy
2.4.2 Hospitals and Clinics
2.4.3 E-commerce and Internet Medical Care
2.5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
2.5.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Market Share by Application (2017-2022)
2.5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue and Market Share by Application (2017-2022)
2.5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Application (2017-2022)
3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment by Company
3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Breakdown Data by Company
3.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Company (2020-2022)
3.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Company (2020-2022)
3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Company (2020-2022)
3.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2020-2022)
3.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2020-2022)
3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Company
3.4 Key Manufacturers DPP-4 Inhibitors for Type 2 Diabetes Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Location Distribution
3.4.2 Players DPP-4 Inhibitors for Type 2 Diabetes Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for DPP-4 Inhibitors for Type 2 Diabetes Treatment by Geographic Region
4.1 World Historic DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Geographic Region (2017-2022)
4.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Geographic Region (2017-2022)
4.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Geographic Region
4.2 World Historic DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country/Region (2017-2022)
4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales by Country/Region (2017-2022)
4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Revenue by Country/Region
4.3 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.4 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.5 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth
4.6 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth
5 Americas
5.1 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country
5.1.1 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
5.1.2 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
5.2 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
5.3 Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region
6.1.1 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2017-2022)
6.1.2 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2017-2022)
6.2 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
6.3 APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment by Country
7.1.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
7.1.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
7.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
7.3 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment by Country
8.1.1 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022)
8.1.2 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022)
8.2 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
8.3 Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment
10.3 Manufacturing Process Analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment
10.4 Industry Chain Structure of DPP-4 Inhibitors for Type 2 Diabetes Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
11.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customer
12 World Forecast Review for DPP-4 Inhibitors for Type 2 Diabetes Treatment by Geographic Region
12.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Region
12.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecast by Region (2023-2028)
12.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecast by Type
12.7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.1.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.2.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Information
13.3.2 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Eli Lilly and Company Main Business Overview
13.3.5 Eli Lilly and Company Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.4.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Boehringer Ingelheim
13.5.1 Boehringer Ingelheim Company Information
13.5.2 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.5.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Boehringer Ingelheim Main Business Overview
13.5.5 Boehringer Ingelheim Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.6.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Takeda Pharmaceutical
13.7.1 Takeda Pharmaceutical Company Information
13.7.2 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.7.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Takeda Pharmaceutical Main Business Overview
13.7.5 Takeda Pharmaceutical Latest Developments
13.8 Mitsubishi Tanabe Pharma
13.8.1 Mitsubishi Tanabe Pharma Company Information
13.8.2 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.8.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Mitsubishi Tanabe Pharma Main Business Overview
13.8.5 Mitsubishi Tanabe Pharma Latest Developments
13.9 LG Life Sciences
13.9.1 LG Life Sciences Company Information
13.9.2 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.9.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 LG Life Sciences Main Business Overview
13.9.5 LG Life Sciences Latest Developments
13.10 Sanwa Kagaku Kenkyusho
13.10.1 Sanwa Kagaku Kenkyusho Company Information
13.10.2 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.10.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Sanwa Kagaku Kenkyusho Main Business Overview
13.10.5 Sanwa Kagaku Kenkyusho Latest Developments
13.11 Dong-A Pharmaceuticals
13.11.1 Dong-A Pharmaceuticals Company Information
13.11.2 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
13.11.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Dong-A Pharmaceuticals Main Business Overview
13.11.5 Dong-A Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. DPP-4 Inhibitors for Type 2 Diabetes Treatment Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Sitagliptin
Table 4. Major Players of Linagliptin
Table 5. Major Players of Vildagliptin
Table 6. Major Players of Saxagliptin
Table 7. Major Players of Alogliptin
Table 8. Major Players of Others
Table 9. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 10. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 11. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2017-2022) & ($ million)
Table 12. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2017-2022)
Table 13. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Type (2017-2022) & (US$/K Unit)
Table 14. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2017-2022)
Table 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2017-2022)
Table 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Application (2017-2022) & (US$/K Unit)
Table 19. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Company (2020-2022) & (M Units)
Table 20. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Company (2020-2022)
Table 21. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2020-2022) ($ Millions)
Table 22. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2020-2022)
Table 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sale Price by Company (2020-2022) & (US$/K Unit)
Table 24. Key Manufacturers DPP-4 Inhibitors for Type 2 Diabetes Treatment Producing Area Distribution and Sales Area
Table 25. Players DPP-4 Inhibitors for Type 2 Diabetes Treatment Products Offered
Table 26. DPP-4 Inhibitors for Type 2 Diabetes Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Geographic Region (2017-2022) & (M Units)
Table 30. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Geographic Region (2017-2022)
Table 31. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country/Region (2017-2022) & (M Units)
Table 34. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country/Region (2017-2022)
Table 35. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 38. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 39. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 41. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 42. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 43. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 44. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 45. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2017-2022) & (M Units)
Table 46. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2017-2022)
Table 47. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2017-2022)
Table 49. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 50. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 51. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 52. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 53. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 54. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 55. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 57. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 58. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 59. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 60. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2017-2022) & (M Units)
Table 62. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2017-2022) & (M Units)
Table 66. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2017-2022) & (M Units)
Table 68. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Table 70. Key Market Challenges & Risks of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Table 71. Key Industry Trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Table 72. DPP-4 Inhibitors for Type 2 Diabetes Treatment Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors List
Table 75. DPP-4 Inhibitors for Type 2 Diabetes Treatment Customer List
Table 76. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Region (2023-2028) & (M Units)
Table 77. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Forecast by Region
Table 78. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 81. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Region (2023-2028) & (M Units)
Table 83. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 85. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2023-2028) & (M Units)
Table 87. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Type (2023-2028) & (M Units)
Table 89. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Type (2023-2028)
Table 90. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Application (2023-2028) & (M Units)
Table 93. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Application (2023-2028)
Table 94. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 96. Merck Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 97. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 98. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 99. Merck Main Business
Table 100. Merck Latest Developments
Table 101. AstraZeneca Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 102. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 103. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 104. AstraZeneca Main Business
Table 105. AstraZeneca Latest Developments
Table 106. Eli Lilly and Company Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 107. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 108. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 109. Eli Lilly and Company Main Business
Table 110. Eli Lilly and Company Latest Developments
Table 111. Novartis Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 112. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 113. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 114. Novartis Main Business
Table 115. Novartis Latest Developments
Table 116. Boehringer Ingelheim Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 117. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 118. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 119. Boehringer Ingelheim Main Business
Table 120. Boehringer Ingelheim Latest Developments
Table 121. Bristol-Myers Squibb Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 122. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 123. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 124. Bristol-Myers Squibb Main Business
Table 125. Bristol-Myers Squibb Latest Developments
Table 126. Takeda Pharmaceutical Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 127. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 128. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 129. Takeda Pharmaceutical Main Business
Table 130. Takeda Pharmaceutical Latest Developments
Table 131. Mitsubishi Tanabe Pharma Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 132. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 133. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 134. Mitsubishi Tanabe Pharma Main Business
Table 135. Mitsubishi Tanabe Pharma Latest Developments
Table 136. LG Life Sciences Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 137. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 138. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 139. LG Life Sciences Main Business
Table 140. LG Life Sciences Latest Developments
Table 141. Sanwa Kagaku Kenkyusho Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 142. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 143. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 144. Sanwa Kagaku Kenkyusho Main Business
Table 145. Sanwa Kagaku Kenkyusho Latest Developments
Table 146. Dong-A Pharmaceuticals Basic Information, DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturing Base, Sales Area and Its Competitors
Table 147. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Offered
Table 148. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue ($ Million), Price (US$/K Unit) and Gross Margin (2020-2022)
Table 149. Dong-A Pharmaceuticals Main Business
Table 150. Dong-A Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Figure 2. DPP-4 Inhibitors for Type 2 Diabetes Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate 2017-2028 (M Units)
Figure 7. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Sitagliptin
Figure 10. Product Picture of Linagliptin
Figure 11. Product Picture of Vildagliptin
Figure 12. Product Picture of Saxagliptin
Figure 13. Product Picture of Alogliptin
Figure 14. Product Picture of Others
Figure 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type in 2021
Figure 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2017-2022)
Figure 17. DPP-4 Inhibitors for Type 2 Diabetes Treatment Consumed in Offline Retail Pharmacy
Figure 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market: Offline Retail Pharmacy (2017-2022) & (M Units)
Figure 19. DPP-4 Inhibitors for Type 2 Diabetes Treatment Consumed in Hospitals and Clinics
Figure 20. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market: Hospitals and Clinics (2017-2022) & (M Units)
Figure 21. DPP-4 Inhibitors for Type 2 Diabetes Treatment Consumed in E-commerce and Internet Medical Care
Figure 22. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market: E-commerce and Internet Medical Care (2017-2022) & (M Units)
Figure 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2017-2022)
Figure 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application in 2021
Figure 25. DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market by Company in 2021 ($ Million)
Figure 26. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company in 2021
Figure 27. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Geographic Region in 2021
Figure 29. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2017-2022)
Figure 30. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country/Region in 2021
Figure 31. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 32. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 33. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 34. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 35. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 36. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales 2017-2022 (M Units)
Figure 38. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue 2017-2022 ($ Millions)
Figure 39. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 40. Americas DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 41. United States DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region in 2021
Figure 46. APAC DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Regions in 2021
Figure 47. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 51. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 54. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 55. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 56. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country in 2021
Figure 61. Middle East & Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country in 2021
Figure 62. Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment in 2021
Figure 68. Manufacturing Process Analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Figure 69. Industry Chain Structure of DPP-4 Inhibitors for Type 2 Diabetes Treatment
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets